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Abstract Cytomegalovirus (CMV) is the most common congenital viral infection, causing
hearing, visual and psychomotor impairment. Preexisting maternal CMV immunity
substantially reduces, but not eliminates, the risk of fetal infection and affectation. This
article is about a case of nonprimary maternal CMV infection during pregnancy, with
vertical transmission, resulting in severe fetal affectation. Preconceptional analysis
indicated maternal CMV past infection. Pregnancy progressed uneventfully until the
20th week ultrasound (US), which revealed cerebral abnormalities: thin and hyper-
echogenic cerebral cortex with prominent lateral ventricles, bilateral periventricular
hyperechogenicities, cerebellar vermis hypoplasia and absent corpus callosum. The
MRI suggested these ﬁndings were compatible with congenital infection rather than
primary brain malformation.
The fetal karyotype was normal. The title of CMV’s IgG antibodies almost tripled. Since the
ﬁrst semester, analysis of the polymerase chain reaction (PCR) for CMVDNA in the amniotic
ﬂuidwas negative. The pregnancywas terminated at 23weeks. Neuropathologicalﬁndings
at autopsy showed severe brain lesions associated with CMV infection.
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Resumo O citomegalovírus (CMV) é a infeção viral congénita que mais comumente causa
deﬁciência auditiva, visual e psicomotora. A preexistência de imunidadematerna reduz
substancialmente, mas não elimina, o risco de infeção e afetação fetal. Trata-se de um
caso de infeção materna não primária por CMV durante a gravidez, com transmissão
vertical, resultando em afetação fetal severa. As análises preconcepção indicavam
infecção passada por CMV. A gravidez decorreu sem intercorrências até a ecograﬁa
efetuada na 20ª semana, que revelou alterações cerebrais: córtex cerebral ﬁno e
hiperecogénico com ventrículos laterais proeminentes, hiperecogenecidades perivent-
riculares bilaterais, hipoplasia do vérmis cerebeloso e ausência de corpo caloso. A
ressonância magnética sugeriu que estes achados eram mais favoráveis a uma infeção
congénita do que com uma malformação cerebral primária. O cariótipo fetal era
normal. O título de anticorpos IgG para CMV havia triplicado desde a dosagem do
primeiro trimestre. O PCR para o DNA do CMV no líquido amniótico foi negativo. A
gravidez foi interrompida na 23ª semana. Os achados neuropatológicos na autópsia
mostraram lesões cerebrais severas associadas a infeção por CMV.
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Introduction
Cytomegalovirus (CMV) is themost common congenital viral
infection, with a birth prevalence of 0,2 to 2,2%,1 causing
hearing and visual impairment and delay of psychomotor
development.1
Primary CMV infection during pregnancy has an inci-
dence of 1 to 4%,2 and the global risk of transplacental
infection is  40%.3,4 The risk of fetal infection increases
with the gestational age1,2,5 (according to a study involving
508 pregnancies, vertical CMV transmission rate by gesta-
tional age at the time of maternal infection was 0% in the
pregestation group, 4.6% in the periconception group, 34.8,
42 and 58.6% respectively in the ﬁrst, second and third
trimester groups).3 Severe disease may affect fetuses in-
fected during the ﬁrst trimester as well as the second, but
rarely affects fetuses infected later on in pregnancy.3,5 Also,
congenital infection impairs placental development and
functions, and should be considered as an underlying cause
of intrauterine growth restriction (IUGR), regardless of virus
transmission to the fetus.6
Ten to 15% of congenitally infected newborns are overtly
symptomatic at birth and will present neurodevelopmental
damage within the ﬁrst three years.1 From those, 20 to 30%
die, mostly of disseminated intravascular coagulation, hepatic
dysfunction, or bacterial superinfection; severe neurologic
morbidity occurs in 50 to 60% of survivors.1,5,7 Of the asymp-
tomatic infants at birth (85 to 90%), 5 to 15% will develop long-
term neurodevelopmental morbidity, such as sensorial hearing
loss, delay of psychomotor development and visual
impairment.1
The criteria necessary to recommend universal screening
for CMV infection in pregnant women haven’t yet been met,
and are not recommended by the Centers for Disease Control
and Prevention or the American College of Obstetricians and
Gynecologists.2,8 Prenatal diagnosis is mainly performed
when US abnormalities are observed.4
Nonprimary maternal CMV infection (reactivation or
reinfection with a different strain) occurs more rarely,
with less probability of fetal infection (1,5% in a study with
543 cases of suspected maternal nonprimary infection)9 and
only 0.2 to 2% of newborns will develop a symptomatic
disease,6 which indicates a minor fetal affectation in these
cases.
This case draws attention to the gravity of a nonprimary
CMV infection.
Case Description
The patient is 37 years old, with irrelevant personal and family
medical histories, and in her fourth spontaneous pregnancy.
The patient has a history of two spontaneous abortions and a
term vaginal delivery, which resulted in a healthy child. The
spouse is healthy; the couple is not consanguineous.
Preconceptional analysis indicated maternal immunity to
Rubella, Toxoplasmosis and CMV. First trimester routine analy-
sis at the 11thweekof pregnancy indicated CMV IgG and IgMof
respectively 848.9 Ul/mL (positive threshold  1) and 0.379 Ul/
mL (negative threshold < 0,8). The ﬁrst trimester US did not
show fetal anomalies, and the combined prenatal screening for
chromosomal abnormalities was negative.
At 20 weeks of gestation, US revealed cerebral abnormali-
ties: thin and hyperechogenic cerebral cortex with promi-
nent lateral ventricles, bilateral periventricular
hyperechogenicities, cerebellar vermis hypoplasia and ab-
sent corpus callosum (►Fig. 1). Amniocentesis was per-
formed and the karyotype was normal (46, XY).
An extended serology study was then performed, and it
showed no immunity to Herpes simplex virus type 2 and
immunity to Toxoplasmosis, Herpes simplex virus type 1,
Parvovirus and CMV. However, CMV IgG title increased almost
three times since theﬁrst trimester analysis, and CMV IgM kept
negative (IgG 2695.0 Ul/mL and IgM 0.333 Ul/mL) – these
serologic tests were performed in the same laboratory as the
ﬁrst trimester tests. IgG avidity testing was high.
When asked about ﬂu–like symptoms, the patient mentions
an episode during the second trimester of pregnancy; however,
as it was mild, it was difﬁcult to precise the time of it.
Magnetic resonance imaging (MRI) at 22 weeks of gesta-
tion conﬁrmed US ﬁndings and raised the hypothesis of
Fig. 1 (A) Ultrasound at 20 weeks of gestation – thin and hyper-
echogenic cerebral cortex with prominent lateral ventricles and
bilateral periventricular hyperechogenicities. (B) Ultrasound at
20 weeks of gestation – cerebellar vermis hypoplasia (arrow).
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fetal infection: “[…] enlargement of the cerebrospinal ﬂuid
circulation spaces at the expense ofmarked reduction in the
thickness of the cerebral parenchyma of both hemispheres
of lissencephalic appearance [...] suggesting serious sequel-
ae of brain infection (group TORCH? other?) rather than
primarymalformative injury of the central nervous system”
(►Fig. 2).
Outcome and Follow-up
The pregnancy was terminated at 23 weeks.
At this time, a new sample of amniotic ﬂuid was
collected to perform PCR for CMV DNA. The result was
negative. Pathologic examination study of fetal and placen-
tal tissues revealed cerebral ventricular dilation with
necro-hemorrhagic and calciﬁed periventricular lesions,
necro-hemorrhagic lesions also at the level of the basal
ganglia, hippocampus, periventricular regions of brainstem
and cerebellar hemispheres. There were areas of four-layer
polymicrogyria and frequent cellular viral inclusions (cy-
tomegalic cells), particularly in the germinal matrix and
near the necrotic lesions. These cells tested positive for
CMV immunohistochemistry (►Figs. 3, 4 and 5). Immuno-
histochemical detection of CMV DNA was found not only in
the fetus brain, but also in his liver, heart and in the
placenta.
Discussion
All the investigation and outcomes in this case suggest a
probable CMV secondary infection, which can be due to a
reactivation or reinfection with a different strain. According
to thematernal serology and themorphologic US performed,
the maternal CMV secondary infection must have occurred
between 11 and 20 weeks of pregnancy.
The preferred approach for diagnosing fetal infection is
PCR testing for DNAvirus in the amniotic ﬂuid,1,3,4which has
a sensitivity of 75–100%.4 Gestational age at amniocentesis
and the time elapsed since the suspicion of infection are
critical factors for the sensitivity of the method.1,3,4
The PCR for CMV DNA negative result was indeed a false
negative. Although this method is recognized as the gold
standard for prenatal diagnosis of fetal CMV infection, the
gestational age and the time lag between maternal infec-
tion and amniocentesis is a critical factor inﬂuencing
sensitivity. To achieve the highest sensitivity, amniocente-
sis should be performed after 21 weeks of gestation and at
least 6 to 7 weeks after the onset of maternal infection
reﬂecting the time it takes for placental infection, trans-
mission to the fetus, viral replication in the fetal kidney,
and excretion into amniotic ﬂuid.1,3,8 In spite of having
fulﬁlled the ﬁrst prerequisite, the time lag might not have
been achieved. Nevertheless, we were reaching the legal
limit for terminating the pregnancy, and even without a
prenatal diagnosis, the US ﬁndings foretold a poor outcome
for the offspring.
The idea that nonprimary CMVmaternal infectionwill not
result in severe fetal sequelae and congenital disease has
been proved different in several published cases.5,10,11 The
preexisting maternal CMV seropositivity substantially re-
duces, but not eliminates, the risk of fetal infection and
affectation; therefore, the use of prenatal invasive methods
for the detection of fetal infection in nonprimary maternal
infections may be justiﬁed.
Neurons migrate from the areas where they are born to
the areas where they will settle into their proper neural
circuits. Neuronal migration starts in the second month of
gestation and is controlled by a complex assortment of
chemical guides and signals. When these signals are absent
or incorrect, neurons do not end up where they belong,
resulting in a primary malformative injury called lissence-
phaly. The lack of gyral development after a defective neuro-
nal migration in the developing brain can be associated with
Fig. 2 Magnetic resonance imaging at 22 weeks of gestation with
lissencephalic appearance.
Fig. 3 Macroscopical ﬁndings – coronal section at the level of the
hippocampus showing dilation of lateral ventricles, extensive white
matter periventricular lesions with focal necro-hemorrhagic lesions at
this level and also at the level of the amygdala/hippocampus and
thalamus.
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the agenesis of the corpus callosum or cerebellar hypoplasia,
and is also due to some genetic syndromes.12
Neuropathological studies of brains infected prenatally
by CMV show evidence of lissencephaly, polymicrogyria,
cerebellar hypoplasia and ventricular dilation in conse-
quence of loss of volume (atrophy),7,12 ﬁndings suggestive
of the severity and risk of neurological andmotor sequelae.
Still, a normal US examination cannot exclude neonatal or
long-term morbidity.1,13 Mild ventriculomegaly, cerebel-
lar vermis hypoplasia and lissencephaly can also be asso-
ciated with extra central nervous system abnormalities,
chromosomal aberration and other fetal infections like
rubella and toxoplasmosis.13 In this case, no other abnor-
malities were found beyond the fetal central nervous
system; the karyotype was normal and the other fetal
infections were excluded.
There is insufﬁcient evidence to support the use of passive
immunization to prevent congenital infection,2 and the only
known means of reducing the risk of congenital CMV is by
reducing exposure to the virus through hygiene measures.2,5
Therapies for treatment of congenital CMV are in the
experimental stage. In an uncontrolled study published in
2005, administration of CMV-speciﬁc hyperimmune globu-
lin to pregnant women with primary CMV infection signiﬁ-
cantly reduced the rate of intrauterine transmission, from 40
to 16%.14 A 2014 randomized placebo-controlled phase 2
trial of virus-speciﬁc hyperimmune globulin for the preven-
tion of congenital CMV infection, involving 124 women with
primary CMV infection from 5 to 26 weeks of gestation,
showed that the treatment with hyperimmune globulin did
not signiﬁcantlymodify the course of primary CMV infection
during pregnancy.15 Other phase 3 studies are under way to
further our understanding of the efﬁcacy and safety of
Fig. 4 Histopathological ﬁndings showing four-layer polymicrogyria (HE). Magniﬁcation, 50x.
Fig. 5 (A) Histopathological ﬁndings – neurons of germinal matrix with
some viral inclusions (arrow), with the typical aspect of cytomegalic cells
(HE). Magniﬁcation, 630x. (B) Histopathological ﬁndings – cells positive for
CMV immunohistochemistry (some showing colocation with the viral
inclusions). Magniﬁcation, 100x.
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hyperimmune globulin administration as a means of pre-
venting congenital CMV infection.
Although it is still not recommended, our institution offers
pregnant women systematic screening for CMV infection, as
well as education about hygienic measures. However, we do
not provide any therapy for pregnant womenwith suspicious
or conﬁrmed CMV primary or nonprimary infections.
Nevertheless, the US and MRI ﬁndings in this case sug-
gested the presence of severe advanced disease and high risk
of long-termneurodevelopmental impairment, so the option
of pregnancy termination was obviously raised.
This article is about a rare case of nonprimary maternal
CMV infection during pregnancy, with vertical transmission,
resulting in severe fetal affectation. The preexistingmaternal
CMV seropositivity substantially reduces, but not eliminates,
the risk of fetal infection and affectation. This article high-
lights the importance of clinical suspicion and the difﬁculty
of prenatal conﬁrmation of a CMV infection.
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